Mexico is emerging as the United States’ most important manufacturing partner, yet investment trends tell a more fragile story. As the 2026 United States–Mexico–Canada Agreement (USMCA) review ...

Intel guided to a supply-constrained first quarter, with supply improvements not expected until Q2 and beyond. Demand for its products looks healthy. But investors ...

Chambers of Commerce are notorious for spending other people’s money; meaning taxpayers they see as an endless supply of more , more and more. The top wish on their “priority list” is passing a local ...

The family-owned company that operates the newspaper cited mounting losses and labor constraints. A final edition is expected on Sunday, May 3. By Mark Walker and Emmett Lindner The family-owned ...

Asking someone, "What's your problem?" can seem like a confrontational challenge. It's like saying, "So, tell me: What's irking you? What is it that's nagging you or getting under your skin, ...

When you're trying to sell your home, a lot of factors go into making it more attractive to buyers and upping its market value. Next to the perfect location, square footage is one of the main elements ...

Currently, users can add a new column with a NOT NULL constraint, and they can drop an existing NOT NULL constraint using ALTER TABLE ... ALTER COLUMN ... However, there’s no support for adding a NOT ...

Despite only operating at the ProTeam level, Laboral Kutxa-Fundación Euskadi have made some of the most interesting signings on the transfer market this year, but won't be delivering on their plans to ...

Dec announced updated full-year 2025 guidance, expecting "total revenue to range from $685 million to $705 million, up from the previous range of $670 million to $700 million, comprised of net product ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

BERLIN — Combining the off-the-shelf anticancer vaccine IO102-IO103 with pembrolizumab does not offer any progression-free survival (PFS) benefit in patients with untreated advanced melanoma vs ...